MB
Moleculin Biotech, Inc.
MBRX · NASDAQ
$0.83 +5.32% (+$0.04)
1M +58.92%
Market Cap $4.43M
P/E Ratio -
Div. Yield -
ROE 816.56%
Bulios Fair Price
$1
20.5% upside
Current Price
$0.83
Undervalued Fair Value Overvalued
According to Bulios Fair Price, MBRX is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
1/9Valuation
100 /100
Cheap P/B 0.38x
EV/EBITDA N/A
P/S N/A
Growth
0 /100
Declining Book val. growth 34.00%
Rev. growth N/A
FCF growth N/A
Profitability
-
N/A Net margin N/A
Op. margin N/A
FCF margin N/A
Quality
0 /100
Poor ROE 816.56%
ROA 143.82%
Asset turnover 0.00x
Debt
54 /100
Moderate Current ratio 0.94x
Int. coverage -387.91x
Debt/Equity 0.03x
Stability
22 /100
Unstable EPS volatility 41.63%
Profitable years 0
Beta 1.92x
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about MBRX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Walter V. Klemp
Employees
17
Headquarters
Houston
Upcoming events
12 NOV
Earnings
Upcoming earnings report